Daewoong Co., Ltd.
003090.KS
Get informed when a big investor buys or sells
+ FollowMarket Cap$628.45B
Close$
$25247.64
68.9% upside
Current Fair Value
68.9% upsideUndervalued by 68.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $628.45 Billion |
|---|---|
| Enterprise Value | $1.34 Trillion |
| Dividend Yield | $200.00 (1.34%) |
| Earnings per Share | $4280 |
| Beta | 0.34 |
| Outstanding Shares | 42,037,000 |
Return
| Return on Equity | 14.32% |
|---|---|
| Return on Assets | 5.16% |
| Return on Invested Capital | 10.61% |
Valuation & Multiples
| P/E Ratio | 3.22 |
|---|---|
| PEG | -26.31 |
| Price to Sales | 0.3 |
| Price to Book Ratio | 0.33 |
| Enterprise Value to Revenue | 0.63 |
| Enterprise Value to EBIT | 5.31 |
| Enterprise Value to Net Income | 7 |
| Total Debt to Enterprise | 0.73 |
| Debt to Equity | 0.78 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$920.23
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$941.56
Average shareholder expectationRevenue Estimate
$341.90 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Daewoong Co., Ltd.
413 employees
CEO: Yeong-Hwan Yoon Operating alongside its various subsidiaries, Daewoong Co., Ltd. is primarily engaged in the production and sale of pharmaceutical products. Additionally, the company generates income from real estate leasing. Established in 1961, the fi...